Woodline Partners’s Monte Rosa Therapeutics GLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.96M Sell
750,884
-212,000
-22% -$3.63M 0.03% 588
2026
Q2
$23.3M Buy
962,884
+888,388
+1,193% +$16.8M 0.07% 335
2026
Q1
$1.23M Buy
+74,496
New +$1.42M ﹤0.01% 858
2023
Q1
– Sell
-511,351
Closed -$3.89M – 697
2022
Q4
$3.89M Buy
511,351
+8,940
+2% +$74.5K 0.05% 354
2022
Q3
$4.1M Buy
502,411
+126,403
+34% +$1.16M 0.06% 336
2022
Q2
$3.64M Buy
376,008
+327,908
+682% +$3.29M 0.06% 305
2022
Q1
$674K Buy
48,100
+75
+0.2% +$1.04K 0.01% 503
2021
Q4
$981K Sell
48,025
-86,008
-64% -$1.8M 0.01% 505
2021
Q3
$2.99M Sell
134,033
-74,035
-36% -$2.12M 0.05% 340
2021
Q2
$4.72M Buy
+208,068
New +$4.24M 0.09% 229

Other funds holding GLUE

Woodline Partners's GLUE Position: Q3 2026 in Review

Woodline Partners reduced its Monte Rosa Therapeutics (GLUE) stake by 22% in Q3 2026, selling an estimated $3.63M and leaving 750,884 shares worth $8.96M. The position accounts for 0.03% of the portfolio, ranked #588.

Woodline Partners first reported a position in GLUE in Q2 2021 and has held it in 10 quarters since. The position peaked at $23.3M in Q2 2026. 190 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

  • Woodline Partners held 750,884 shares of Monte Rosa Therapeutics worth $8.96M as of Q3 2026.
  • Woodline Partners sold 212,000 Monte Rosa Therapeutics shares in Q3 2026, an estimated $3.63M.
  • Monte Rosa Therapeutics made up 0.03% of Woodline Partners's portfolio in Q3 2026, its #588 holding.
  • Woodline Partners first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 10 quarters since.
  • Woodline Partners's Monte Rosa Therapeutics position peaked at $23.3M in Q2 2026.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.